[
  {
    "ts": "2025-10-18T13:05:36+00:00",
    "headline": "AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin",
    "summary": "AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.",
    "url": "https://finance.yahoo.com/news/abbvie-completes-acquisition-gilgamesh-pharmaceuticals-130536603.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "a47cab35-a929-3e52-aaeb-e579dc0f0a7c",
      "content": {
        "id": "a47cab35-a929-3e52-aaeb-e579dc0f0a7c",
        "contentType": "STORY",
        "title": "AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin",
        "description": "",
        "summary": "AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.",
        "pubDate": "2025-10-18T13:05:36Z",
        "displayTime": "2025-10-18T13:05:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/66c6590c94d0f93ba894c14d0895690d",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/abbvie-completes-acquisition-of-gilgamesh-pharmaceuticals-bretisilocin-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m6ibw8wTOutmCnQKc3D.JQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/66c6590c94d0f93ba894c14d0895690d.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NaD9ymG69w04qqwH8CEn_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/66c6590c94d0f93ba894c14d0895690d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-completes-acquisition-gilgamesh-pharmaceuticals-130536603.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-completes-acquisition-gilgamesh-pharmaceuticals-130536603.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]